ArticleInternational journal of nanomedicine2012
Mannosylated liposomes for targeted gene delivery.
Article in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 63 citations in OpenAlex.
- Review
- Targeted Hepatic Delivery of Bioactive Molecules via Nanovesicles: Recent Developments and Emerging Directions.Journal of personalized medicine · 2025Review
- Photosensitive and dual-targeted chromium nanoparticle delivering small interfering RNA YTHDF1 for molecular-targeted immunotherapy in liver cancer.Journal of nanobiotechnology · 2024Article
- Inhibition of the MALT1-LPCAT3 axis protects cartilage degeneration and osteoarthritis.Cell communication and signaling : CCS · 2024Article
- Article
- Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design.Frontiers in immunology · 2023Review
- Lipid nanoparticles for antisense oligonucleotide gene interference into brain border-associated macrophages.Frontiers in molecular biosciences · 2022Article
- Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines.Pharmaceutics · 2021Article
- Lipid-based gene delivery to macrophage mitochondria for atherosclerosis therapy.Pharmacology research & perspectives · 2020Review
- Colorectal cancer combination therapy using drug and gene co-delivered, targeted poly(ethylene glycol)-ε-poly(caprolactone) nanocarriers.Drug design, development and therapy · 2018Article
- Targeted delivery of mannosylated-PLGA nanoparticles of antiretroviral drug to brain.International journal of nanomedicine · 2018Article
- Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.International journal of nanomedicine · 2015Article
- Ultrasound effects on brain-targeting mannosylated liposomes: in vitro and blood-brain barrier transport investigations.Drug design, development and therapy · 2015Article
- Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin.International journal of nanomedicine · 2014Article
- Transferrin-PEG-PE modified dexamethasone conjugated cationic lipid carrier mediated gene delivery system for tumor-targeted transfection.International journal of nanomedicine · 2012Article
- Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.International journal of molecular sciences · 2012Review
- Comparison of two kinds of nanomedicine for targeted gene therapy: premodified or postmodified gene delivery systems.International journal of nanomedicine · 2012Article
- Better, Faster, Stronger: Accelerating mRNA-Based Immunotherapies With Nanocarriers.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
- DNA vaccination for prostate cancer: key concepts and considerations.Cancer nanotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiposomes can be modified with different ligands to control their biological properties, such as longevity, targeting ability, and intracellular penetration, in a desired fashion. The aim of this study was to modify liposomes with a novel mannosylated polyethylene glycol-phosphatidylethanolamine (M-PEG-PE) ligand to achieve active targeted gene delivery.
methodsRat Kupffer cells were isolated and used as model cells for in vitro evaluation of cytotoxicity and transfection efficiency. The modified liposomes were intravenously injected into the rats, and Kupffer cells were isolated and analyzed by flow cytometry for in vivo gene delivery and expression.
resultsThe M-PEG-PE-modified liposome-enhanced green fluorescence protein plasmid (M-PEG-PE-Lipo-pEGFP) complexes had a particle size of 237 nm and a loading efficiency of 90%. The M-PEG-PE-Lipo-pEGFP complexes displayed remarkably higher transfection efficiency than unmodified Lipo-pEGFP, both in vitro (51%-30%) and in vivo (43%-27%).
conclusionM-PEG-PE could function as an excellent active targeting ligand, and M-PEG-PE-modified liposomes could be promising active targeted drug delivery vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.